Brief: Liminal Biosciences Announces FDA Approval For Its Biologics License Application For Ryplazim (Plasminogen, Human-Tvmh)
04/06/2021 20:34
June 4 (Reuters) - Liminal BioSciences Inc LMNL.O :
* LIMINAL BIOSCIENCES ANNOUNCES FDA APPROVAL FOR ITS
BIOLOGICS
LICENSE APPLICATION FOR RYPLAZIM® (PLASMINOGEN, HUMAN-TVMH)
* LIMINAL BIOSCIENCES INC - FDA APPROVED RYPLAZIM FOR
TREATMENT
OF PATIENTS WITH PLASMINOGEN DEFICIENCY TYPE 1 THROUGH UNIT
PROMETIC BIOTHERAPEUTICS
Source text for Eikon: ID:nCNWJ95mha
Further company coverage: LMNL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Liminal BioSciences
See all newsBrief: Liminal Biosciences Announces Completion Of The Plan Of Arrangement With Structured Alpha Lp
Brief: Liminal Biosciences Files Amended Schedule 13E-3 And Supplement To Management Information Circular
Brief: Liminal Biosciences Obtains Interim Order For Proposed Arrangement With Structured Alpha Lp
U.S. STOCKS ON THE MOVE-Liminal Biosciences, Tesla, Quad/Graphics
U.S. STOCKS ON THE MOVE-T2 Biosystems, GoodRx Holdings, ShiftPixy